Our profiles of the finalists for this year’s Xconomy Awards roll on today with a look at the nominees for the Contrarian award.
These finalists have been nominated for different reasons. One, for instance, may have paved the way for gene therapies to be commercially adopted in the U.S., by being the first insurer to agree to a new type of payment model. This could be exceedingly important in the years to come as more pricey therapies head to the FDA for approval. Another nominee is building a closely watched biotech in a very unusual way, and another is taking a… Read more »
UNDERWRITERS AND PARTNERS